Understanding how antibodies can protect against Klebsiella pneumoniae infections
Official title: Antibody mediated immunity against Klebsiella pneumoniae
Funded at Massachusetts General Hospital · NIH-10993142 · Data updated 2026-11-12
This study is looking at how our immune system reacts to a type of bacteria called Klebsiella pneumoniae, which can cause serious infections, especially in kids, to help create better vaccines that protect against it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | December 1, 2023 |
| Project end | October 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $693,822 |
| NIH project number | 5R01AI175345-02 |
| Project ID | NIH-10993142 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children under 11 years old who are at risk for infections caused by Klebsiella pneumoniae.
✕Less likely to help
Patients who are not at risk for Klebsiella pneumoniae infections or those who are older than 11 years may not benefit from this research.
What this research studies
This research investigates the immune response to Klebsiella pneumoniae, a significant cause of infections and mortality, particularly in children. The project aims to identify how different subtypes of the bacteria trigger antibody responses in humans, which is crucial for developing effective vaccines. By studying the immune responses to various K. pneumoniae O-antigens, the research seeks to inform the design of a vaccine that could provide broader protection against this pathogen. The findings could lead to improved strategies for preventing infections caused by antibiotic-resistant strains of Klebsiella pneumoniae.
Why it matters
Potential benefit: If successful, this research could lead to the development of a vaccine that significantly reduces infections and mortality associated with Klebsiella pneumoniae, especially in vulnerable populations like children.
How similar studies have gone: Previous research has shown promise in developing vaccines for bacterial infections, indicating that this approach could yield significant advancements in vaccine development for Klebsiella pneumoniae.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Harris, Jason B — Massachusetts General Hospital
- Study coordinator: Harris, Jason B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.